Form 4: Eli Lilly Exec Buys $647K in Stock

Eli Lilly's EVP and President of Lilly Oncology, Jacob Van Naarden, purchased 1,000 shares of company common stock for over $647,000 as part of a pre-planned transaction.

Summary

• Jacob Van Naarden, Executive Vice President and President of Lilly Oncology at Eli Lilly & Co., acquired 1,000 shares of the company's common stock.
• The transaction occurred on August 13, 2025, at a price of $647.36 per share.
• The total value of the acquired shares is $647,360.
• Following this transaction, Mr. Van Naarden directly holds 20,561.985 shares.
• He also indirectly holds 4,342 shares through the Van Naarden Family Trust and 4,302 shares through his spouse.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled purchase.

Sentiment

Score: 8

Explanation: The purchase of a significant amount of company stock by a high-ranking executive, especially under a Rule 10b5-1 plan, indicates strong insider confidence in the company's future prospects and valuation.

Positives

• An executive's purchase of company stock signals confidence in the company's future prospects and valuation.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned, non-discretionary purchase, which often suggests a long-term investment perspective.

Future Outlook

The transaction, executed under a Rule 10b5-1 plan, indicates a pre-scheduled purchase of shares, reflecting a long-term investment strategy rather than a reaction to immediate market conditions.

Management Comments

• The filing includes a signature by Jonathan Groff for Jacob Van Naarden, pursuant to authorization on file.

Industry Context

Insider purchases, particularly by high-ranking executives in the pharmaceutical sector like the President of Oncology, can be interpreted as a positive signal regarding the company's future drug pipeline, regulatory approvals, or market positioning within a competitive industry.

Comparison to Industry Standards

• While specific comparable transactions are not detailed, insider buying by senior executives is generally viewed favorably across all industries, including pharmaceuticals. For example, similar purchases by executives at companies like Pfizer or Merck would typically be interpreted as a strong vote of confidence in their respective pipelines or strategic directions, aligning with the positive sentiment associated with this transaction at Eli Lilly.

Related Party Transactions

• The filing discloses indirect beneficial ownership of shares through the Van Naarden Family Trust (4,342 shares) and by the reporting person's spouse (4,302 shares), which are considered related party holdings.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, potentially increasing confidence in the stock.
• Employees might see this as a sign of management's commitment and belief in the company's long-term success.

Key Dates

Recommendation

The purchase of a substantial amount of company stock by a key executive, particularly the President of Oncology, signals strong insider confidence in Eli Lilly's future, likely driven by expectations of continued growth, pipeline success, or favorable market conditions. This insider buying activity, especially when executed under a Rule 10b5-1 plan, suggests a deliberate long-term investment perspective, making it a positive indicator for potential investors.

Keywords

Eli Lilly, LLY, insider trading, stock purchase, executive, oncology, pharmaceutical, Form 4, Jacob Van Naarden, Rule 10b5-1